Yahoo Web Search

Search results

1. • 

     When Chemotherapy Doesn't Work, Immune Therapy May Offer New Hope

     Verywell Health via Yahoo News· 10 months ago

     Immune therapies like Columvi give patients with relapsed or refractory diffuse large B-cell...

2. • 

     Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

     Zacks via Yahoo Finance· 6 months ago

     Regeneron Pharmaceuticals, Inc. REGN announced positive results from the phase I/II study on its...

3. • 

     Regeneron's (REGN) Application for Blood Cancer Drug Accepted

     Zacks via Yahoo Finance· 10 months ago

     Regeneron's (REGN) application seeking approval of odronextamab for patients with...

4. • 

     Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

     Insider Monkey via Yahoo Finance· 1 month ago

     Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate...

5. • 

     Regeneron (REGN) Presents Positive Data on MM and FL Drugs

     Zacks via Yahoo Finance· 2 years ago

     Regeneron Pharmaceuticals, Inc. REGN announced positive initial data from a mid-stage study on...

6. • 

     New HIV Vaccine Trial Shows Extreme Promise

     Plus via Yahoo News· 2 years ago

     A small, phase 1 trial testing a new HIV vaccine delivered positive results in 97 percent of recipients. The vaccine was created from an engineered...

7. • 

     Apexigen Touts New Positive Sotigalimab Data Showing Expanded Anti-Tumor Responses

     Benzinga via Yahoo Finance· 1 year ago

     Apexigen Inc (NASDAQ: APGN) announced the presentation of new data from Phase 2 multicenter clinical...

8. • 

     The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca

     Zacks via Yahoo Finance· 10 months ago

     For Immediate Release Chicago, IL – August 29, 2023 – Zacks.com announces the list of stocks...

9. • Q2 2023 Fate Therapeutics Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 10 months ago

     Participants Bahram Valamehr; Chief Research & Development Officer; Fate Therapeutics, Inc. Edward J. Dulac; CFO; Fate Therapeutics, Inc. J. Scott Wolchko; Founder, CEO, President & Director ...

10. • 

      Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

      Insider Monkey via Yahoo Finance· 3 months ago

      Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A....